{"id":"tnf-inhibitor","rwe":[],"tags":[],"safety":{"safetySignals":[{"date":"","signal":"ANAEMIA","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"CARDIAC DISORDER","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"CARDIAC VALVE DISEASE","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"CARDIAC VALVE VEGETATION","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"CEREBROVASCULAR ACCIDENT","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"COORDINATION ABNORMAL","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"DEAFNESS","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"EMBOLISM","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"HYPOKINESIA","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"HYPOTONIA","source":"FDA FAERS","actionTaken":"Reported 1 times"}],"drugInteractions":[{"drug":"Abatacept","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Anakinra","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Azathioprine","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Cyclophosphamide","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Glatiramer","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Hydroxychloroquine","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Immunosuppressants","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Live vaccines","action":"Avoid","effect":"Increased risk of infections"},{"drug":"Methotrexate","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Mycophenolate","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Rituximab","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Thalidomide","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Vaccines (non-live)","action":"Avoid","effect":"Decreased response to vaccine"}],"commonSideEffects":[{"effect":"Upper respiratory tract infection","drugRate":"21.9%","placeboRate":"","totalAtRisk":1455,"totalAffected":319,"trialsReporting":1},{"effect":"Bronchitis","drugRate":"15.2%","placeboRate":"","totalAtRisk":1455,"totalAffected":221,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"13.1%","placeboRate":"","totalAtRisk":1455,"totalAffected":190,"trialsReporting":1},{"effect":"Rheumatoid arthritis","drugRate":"12.6%","placeboRate":"","totalAtRisk":1455,"totalAffected":183,"trialsReporting":1},{"effect":"Fall","drugRate":"12.2%","placeboRate":"","totalAtRisk":1455,"totalAffected":177,"trialsReporting":1},{"effect":"Herpes zoster","drugRate":"12.0%","placeboRate":"","totalAtRisk":1455,"totalAffected":175,"trialsReporting":1},{"effect":"Nasopharyngitis","drugRate":"11.5%","placeboRate":"","totalAtRisk":1455,"totalAffected":168,"trialsReporting":1},{"effect":"Hypertension","drugRate":"8.9%","placeboRate":"","totalAtRisk":1455,"totalAffected":129,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"7.6%","placeboRate":"","totalAtRisk":1455,"totalAffected":111,"trialsReporting":1},{"effect":"Lymphopenia","drugRate":"7.4%","placeboRate":"","totalAtRisk":1455,"totalAffected":107,"trialsReporting":1},{"effect":"Back pain","drugRate":"6.9%","placeboRate":"","totalAtRisk":1455,"totalAffected":101,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"6.8%","placeboRate":"","totalAtRisk":1455,"totalAffected":99,"trialsReporting":1},{"effect":"Sinusitis","drugRate":"6.7%","placeboRate":"","totalAtRisk":1455,"totalAffected":97,"trialsReporting":1},{"effect":"Influenza","drugRate":"6.3%","placeboRate":"","totalAtRisk":1455,"totalAffected":92,"trialsReporting":1},{"effect":"Latent tuberculosis","drugRate":"6.1%","placeboRate":"","totalAtRisk":1455,"totalAffected":89,"trialsReporting":1},{"effect":"Pharyngitis","drugRate":"6.0%","placeboRate":"","totalAtRisk":1455,"totalAffected":87,"trialsReporting":1},{"effect":"Osteoarthritis","drugRate":"5.8%","placeboRate":"","totalAtRisk":1455,"totalAffected":84,"trialsReporting":1},{"effect":"Cough","drugRate":"5.3%","placeboRate":"","totalAtRisk":1455,"totalAffected":77,"trialsReporting":1},{"effect":"Anaemia","drugRate":"5.2%","placeboRate":"","totalAtRisk":1455,"totalAffected":75,"trialsReporting":1},{"effect":"Nausea","drugRate":"4.6%","placeboRate":"","totalAtRisk":1455,"totalAffected":67,"trialsReporting":1},{"effect":"Alanine aminotransferase increased","drugRate":"4.6%","placeboRate":"","totalAtRisk":1455,"totalAffected":67,"trialsReporting":1},{"effect":"Gastroenteritis","drugRate":"4.2%","placeboRate":"","totalAtRisk":1455,"totalAffected":61,"trialsReporting":1},{"effect":"Headache","drugRate":"3.4%","placeboRate":"","totalAtRisk":1455,"totalAffected":50,"trialsReporting":1}],"contraindications":["Severe Heart Failure (NYHA class III-IV)","Active Tuberculosis","Active Sepsis or Serious Infections","Demyelinating Diseases","Latent Tuberculosis","Hepatitis B","Recurrent Infections","Mild-to-moderate Heart Failure (NYHA Class I-II)","Hepatitis C Infection","HIV Infection","Malignancy History","Live Vaccines","Combination with Other Immunosuppressants"],"specialPopulations":{"Pregnancy":"Women with chronic inflammatory diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), or inflammatory bowel disease (IBD), who are exposed to TNF inhibitors during pregnancy and postpartum may have a numerically higher risk for serious infection, but the association is not statistically significant.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tnf-inhibitor","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:31:09.144272+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:31:14.957204+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:31:09.216368+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tnf-inhibitor","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:31:15.283038+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3897557/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:31:16.745747+00:00"}},"allNames":"tnf inhibitor","offLabel":[],"timeline":[],"aiSummary":"Pfizer's TNF Inhibitor is a marketed drug with a revenue of $21.2B. It is used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, and Crohn's Disease. The drug has undergone 100 trials and has 1313 publications. It is a monoclonal antibody that targets TNF-alpha, a key cytokine involved in inflammation. This mechanism allows it to reduce inflammation and slow disease progression. The commercial significance of TNF Inhibitor lies in its ability to provide relief to millions of patients worldwide. Pfizer continues to develop its pipeline, including potential new indications and formulations for TNF Inhibitor.","brandName":"TNF Inhibitor","ecosystem":[],"isGeneric":true,"mechanism":{"target":"TNF-alpha","novelty":"Best-in-class","modality":"Monoclonal Antibody","drugClass":"Monoclonal Antibody","explanation":"","oneSentence":"","technicalDetail":"TNF Inhibitor works by binding to TNF-alpha and preventing it from interacting with its receptor. This prevents the activation of immune cells and the production of other inflammatory molecules. As a result, inflammation is reduced and disease progression is slowed. TNF Inhibitor is administered via injection and has a rapid onset of action."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$17,767","genericStatus":"Biologic — patent protected","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=tnf-inhibitor","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tnf-inhibitor","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:32:32.803662+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Humira (adalimumab)","company":"AbbVie","advantage":"Established efficacy and long-term data supporting use in RA, strong physician familiarity, extensive global marketing networks, and consistent biosimilar pipeline expansion to drive down costs"},{"name":"Amjevita","company":"Eli Lilly and Company","advantage":"Biosimilar of Humira with similar efficacy at lower costs"},{"name":"Imraldi","company":"Sandoz","advantage":"Biosimilar of Humira with similar efficacy at lower costs"},{"name":"Abatacept (Orencia)","company":"Bristol Myers Squibb","advantage":"Reliable clinical efficacy in refractory rheumatoid arthritis, especially among patients non-responsive to TNF inhibitors"},{"name":"Rituximab (Rituxan or MabThera)","company":"Genentech (Roche)","advantage":"B Cell Depletion Therapy with significant competitor in the RA market"},{"name":"Tofacitinib","company":"Pfizer","advantage":"Novel oral therapy that challenges established TNF inhibitors with similar efficacy at lower costs"}],"genericName":"tnf-inhibitor","indications":{"approved":[{"name":"Rheumatoid Arthritis","regulator":"FDA"},{"name":"Psoriatic Arthritis","regulator":"FDA"},{"name":"Ankylosing Spondylitis","regulator":"FDA"},{"name":"Ulcerative Colitis","regulator":"FDA"},{"name":"Crohn's Disease","regulator":"FDA"},{"name":"Plaque Psoriasis","regulator":"FDA"},{"name":"Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Axial Spondyloarthritis","regulator":"FDA"},{"name":"Psoriatic Arthritis with Distal Interphalangeal Involvement","regulator":"FDA"},{"name":"Moderate to Severe Ulcerative Colitis","regulator":"FDA"},{"name":"Non-Radiographic Axial Spondyloarthritis","regulator":"FDA"},{"name":"Moderate to Severe Plaque Psoriasis","regulator":"FDA"},{"name":"Active Ankylosing Spondylitis","regulator":"FDA"},{"name":"Moderate to Severe Crohn's Disease","regulator":"FDA"},{"name":"Moderate to Severe Rheumatoid Arthritis","regulator":"FDA"},{"name":"Active Psoriatic Arthritis","regulator":"FDA"},{"name":"Moderate to Severe Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Active Ulcerative Colitis","regulator":"FDA"},{"name":"Active Crohn's Disease","regulator":"FDA"},{"name":"Active Plaque Psoriasis","regulator":"FDA"},{"name":"Active Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Psoriatic Arthritis with Distal Interphalangeal Involvement","regulator":"FDA"},{"name":"Active Non-Radiographic Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Active Ankylosing Spondylitis","regulator":"FDA"},{"name":"Active Crohn's Disease","regulator":"FDA"},{"name":"Active Ulcerative Colitis","regulator":"FDA"},{"name":"Active Rheumatoid Arthritis","regulator":"FDA"},{"name":"Active Psoriatic Arthritis","regulator":"FDA"},{"name":"Active Plaque Psoriasis","regulator":"FDA"},{"name":"Active Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Active Non-Radiographic Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Ankylosing Spondylitis","regulator":"FDA"},{"name":"Active Crohn's Disease","regulator":"FDA"},{"name":"Active Ulcerative Colitis","regulator":"FDA"},{"name":"Active Rheumatoid Arthritis","regulator":"FDA"},{"name":"Active Psoriatic Arthritis","regulator":"FDA"},{"name":"Active Plaque Psoriasis","regulator":"FDA"},{"name":"Active Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Active Non-Radiographic Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Ankylosing Spondylitis","regulator":"FDA"},{"name":"Active Crohn's Disease","regulator":"FDA"},{"name":"Active Ulcerative Colitis","regulator":"FDA"},{"name":"Active Rheumatoid Arthritis","regulator":"FDA"},{"name":"Active Psoriatic Arthritis","regulator":"FDA"},{"name":"Active Plaque Psoriasis","regulator":"FDA"},{"name":"Active Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Active Non-Radiographic Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Ankylosing Spondylitis","regulator":"FDA"},{"name":"Active Crohn's Disease","regulator":"FDA"},{"name":"Active Ulcerative Colitis","regulator":"FDA"},{"name":"Active Rheumatoid Arthritis","regulator":"FDA"},{"name":"Active Psoriatic Arthritis","regulator":"FDA"},{"name":"Active Plaque Psoriasis","regulator":"FDA"},{"name":"Active Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Active Non-Radiographic Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Ankylosing Spondylitis","regulator":"FDA"},{"name":"Active Crohn's Disease","regulator":"FDA"},{"name":"Active Ulcerative Colitis","regulator":"FDA"},{"name":"Active Rheumatoid Arthritis","regulator":"FDA"},{"name":"Active Psoriatic Arthritis","regulator":"FDA"},{"name":"Active Plaque Psoriasis","regulator":"FDA"},{"name":"Active Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Active Non-Radiographic Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Ankylosing Spondylitis","regulator":"FDA"},{"name":"Active Crohn's Disease","regulator":"FDA"},{"name":"Active Ulcerative Colitis","regulator":"FDA"},{"name":"Active Rheumatoid Arthritis","regulator":"FDA"},{"name":"Active Psoriatic Arthritis","regulator":"FDA"},{"name":"Active Plaque Psoriasis","regulator":"FDA"},{"name":"Active Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Active Non-Radiographic Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Ankylosing Spondylitis","regulator":"FDA"},{"name":"Active Crohn's Disease","regulator":"FDA"},{"name":"Active Ulcerative Colitis","regulator":"FDA"},{"name":"Active Rheumatoid Arthritis","regulator":"FDA"},{"name":"Active Psoriatic Arthritis","regulator":"FDA"},{"name":"Active Plaque Psoriasis","regulator":"FDA"},{"name":"Active Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Active Non-Radiographic Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Ankylosing Spondylitis","regulator":"FDA"},{"name":"Active Crohn's Disease","regulator":"FDA"},{"name":"Active Ulcerative Colitis","regulator":"FDA"},{"name":"Active Rheumatoid Arthritis","regulator":"FDA"},{"name":"Active Psoriatic Arthritis","regulator":"FDA"},{"name":"Active Plaque Psoriasis","regulator":"FDA"},{"name":"Active Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Active Non-Radiographic Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Ankylosing Spondylitis","regulator":"FDA"},{"name":"Active Crohn's Disease","regulator":"FDA"},{"name":"Active Ulcerative Colitis","regulator":"FDA"},{"name":"Active Rheumatoid Arthritis","regulator":"FDA"},{"name":"Active Psoriatic Arthritis","regulator":"FDA"},{"name":"Active Plaque Psoriasis","regulator":"FDA"},{"name":"Active Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Active Non-Radiographic Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Ankylosing Spondylitis","regulator":"FDA"},{"name":"Active Crohn's Disease","regulator":"FDA"},{"name":"Active Ulcerative Colitis","regulator":"FDA"},{"name":"Active Rheumatoid Arthritis","regulator":"FDA"},{"name":"Active Psoriatic Arthritis","regulator":"FDA"},{"name":"Active Plaque Psoriasis","regulator":"FDA"},{"name":"Active Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Active Non-Radiographic Axial Spondyloarthritis","regulator":"FDA"},{"name":"Active Ankylosing Spondylitis","regulator":"FDA"},{"name":"Active Crohn's Disease","regulator":"FDA"},{"name":"Active Ulcerative Colitis","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07477795","phase":"PHASE2","title":"Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04-01","conditions":"Takayasu Arteritis, Large Vessel Vasculitis","enrollment":52},{"nctId":"NCT07491913","phase":"NA","title":"Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-06-15","conditions":"Takayasu Arteritis","enrollment":40},{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT07448402","phase":"","title":"Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease","status":"NOT_YET_RECRUITING","sponsor":"Caja Costarricense de Seguro Social","startDate":"2026-05","conditions":"Psoriasis, Psoriasis Arthritis, Psoriasis (PsO)","enrollment":50},{"nctId":"NCT07453628","phase":"","title":"Association of Erectile Dysfunction With Neuropathic Pain, Disease Activity, and Functional Status in Male Patients With Axial Spondyloarthritis: A Cross-Sectional Observational Study","status":"COMPLETED","sponsor":"Altuğ Güner","startDate":"2021-02-03","conditions":"Ankylosing Spondylitis, Sexual Dysfunction","enrollment":90},{"nctId":"NCT00385086","phase":"PHASE3","title":"Lumbar Spinal Fibrosis and TNF Alpha Inhibition","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-02","conditions":"Post Operative Sciatica by Lumbar Spinal Fibrosis","enrollment":38},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT06905288","phase":"","title":"Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-02","conditions":"Ankylosing Spondylitis","enrollment":70},{"nctId":"NCT06712628","phase":"","title":"A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-11-07","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":678},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT07293910","phase":"PHASE2","title":"Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Tanta University","startDate":"2026-02-15","conditions":"HELICOBACTER PYLORI INFECTIONS, Helicobacter Infection, Helicobacter Pylori Gastrointestinal Tract Infection","enrollment":66},{"nctId":"NCT05950724","phase":"EARLY_PHASE1","title":"RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant","status":"ENROLLING_BY_INVITATION","sponsor":"Northwestern University","startDate":"2023-09-17","conditions":"Lung Transplant; Complications","enrollment":20},{"nctId":"NCT06440629","phase":"PHASE4","title":"Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)","status":"RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2024-08-20","conditions":"Rheumatoid Arthritis","enrollment":350},{"nctId":"NCT07386587","phase":"PHASE3","title":"Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis","status":"ENROLLING_BY_INVITATION","sponsor":"University of Child Health Sciences and Children's Hospital, Lahore","startDate":"2026-01-27","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT05306353","phase":"PHASE2","title":"CD40L Antagonism in Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-07-25","conditions":"Rheumatoid Arthritis","enrollment":2},{"nctId":"NCT02714881","phase":"","title":"Lipids, Inflammation, and CV Risk in RA","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-10-17","conditions":"Rheumatoid Arthritis, Cardiovascular Disease","enrollment":74},{"nctId":"NCT07117344","phase":"","title":"Biomarkers in Ankylosing Spondylitis","status":"RECRUITING","sponsor":"Kirsehir Ahi Evran Universitesi","startDate":"2026-01-15","conditions":"Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA)","enrollment":160},{"nctId":"NCT07349472","phase":"PHASE2","title":"Pentoxifylline in Patients With Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Ihab Elsayed Hassan","startDate":"2026-01-20","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT06538870","phase":"NA","title":"Dental Implant Healing With TNF-Alpha Inhibitors","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-06-28","conditions":"Edentulism, Dental Implants, TNF-alpha Inhibitors","enrollment":30},{"nctId":"NCT06125197","phase":"PHASE1","title":"Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2024-07-23","conditions":"Lung Cancer","enrollment":22},{"nctId":"NCT05590455","phase":"PHASE2","title":"Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-11","conditions":"Tuberculous Meningitis, HIV I Infection","enrollment":130},{"nctId":"NCT03739853","phase":"PHASE4","title":"Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-14","conditions":"Psoriatic Arthritis","enrollment":192},{"nctId":"NCT07237906","phase":"","title":"Neutropenia With TNF-α Inhibitors","status":"COMPLETED","sponsor":"Burak Ugur Cetin","startDate":"2023-09-01","conditions":"Neutropenia, TNF-alpha Inhibitors","enrollment":122},{"nctId":"NCT01022749","phase":"PHASE3","title":"Efficacy Safety Study of Flu Vaccine in Immunodepression Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-09","conditions":"Inflammatory Bowel Disease (IBD)","enrollment":228},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":"Colorectal Cancer, Hematologic Malignancy, Rectum Cancer","enrollment":12},{"nctId":"NCT05271318","phase":"PHASE1, PHASE2","title":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.","status":"RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2022-05-17","conditions":"Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma","enrollment":29},{"nctId":"NCT03123120","phase":"PHASE2","title":"A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-06-07","conditions":"Colitis, Ulcerative","enrollment":22},{"nctId":"NCT03792841","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC","status":"TERMINATED","sponsor":"Amgen","startDate":"2019-02-05","conditions":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer","enrollment":212},{"nctId":"NCT05379322","phase":"PHASE3","title":"The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients","status":"WITHDRAWN","sponsor":"Abu Dhabi Stem Cells Center","startDate":"2023-03-01","conditions":"Rheumatoid Arthritis","enrollment":0},{"nctId":"NCT05428488","phase":"PHASE3","title":"Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2022-11-28","conditions":"Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT07181694","phase":"PHASE1","title":"A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-12","conditions":"Healthy Adult Male","enrollment":444},{"nctId":"NCT07198113","phase":"","title":"COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)","status":"NOT_YET_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-11-01","conditions":"Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease","enrollment":1100},{"nctId":"NCT07184853","phase":"NA","title":"Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-25","conditions":"Graft vs Host Disease","enrollment":122},{"nctId":"NCT07166315","phase":"","title":"Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor","status":"RECRUITING","sponsor":"Adelphi Real World","startDate":"2025-07-07","conditions":"Axial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA)","enrollment":700},{"nctId":"NCT07140666","phase":"","title":"Analysis of Influence Factors on Osteopenia in Different Treatment of Psoriasis","status":"COMPLETED","sponsor":"Chongli Yu","startDate":"2022-08-01","conditions":"Psoriasis","enrollment":100},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT07113834","phase":"","title":"Characteristics of Ankylosing Spondylitis Associated Uveitis","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-09-01","conditions":"Uveitis","enrollment":22},{"nctId":"NCT05222932","phase":"PHASE1","title":"Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1","status":"ACTIVE_NOT_RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2023-03-08","conditions":"Melanoma, Head and Neck Squamous Cell Carcinoma","enrollment":15},{"nctId":"NCT06418529","phase":"","title":"A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-15","conditions":"Rheumatoid Arthritis","enrollment":21340},{"nctId":"NCT03915964","phase":"PHASE4","title":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-25","conditions":"Rheumatoid Arthritis","enrollment":2663},{"nctId":"NCT03358693","phase":"","title":"Molecular Signatures in Inflammatory Skin Disease","status":"RECRUITING","sponsor":"Prof. Dr. Stephan Weidinger","startDate":"2017-01-20","conditions":"Atopic Dermatitis, Psoriasis","enrollment":300},{"nctId":"NCT04086745","phase":"PHASE4","title":"A Study of Baricitinib in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-14","conditions":"Rheumatoid Arthritis","enrollment":1317},{"nctId":"NCT04817072","phase":"NA","title":"Evaluation of Mood Disorders Under Biologics in Chronic Inflammatory Rheumatic Disease","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2021-05-19","conditions":"Rheumatic Diseases, Mood Disorders","enrollment":108},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT05080218","phase":"PHASE4","title":"COVID-19 VaccinE Response in Rheumatology Patients","status":"COMPLETED","sponsor":"Jeffrey Curtis","startDate":"2021-11-15","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis","enrollment":841},{"nctId":"NCT06281106","phase":"PHASE2, PHASE3","title":"TYK2 Inhibition in Paradoxical Psoriasis","status":"TERMINATED","sponsor":"Prof Curdin Conrad","startDate":"2024-06-20","conditions":"Psoriasis","enrollment":2},{"nctId":"NCT00740103","phase":"PHASE2","title":"Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2002-12","conditions":"Crohn's Disease","enrollment":119},{"nctId":"NCT06653634","phase":"PHASE4","title":"Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-10-24","conditions":"Juvenile Idiopathic Arthritis","enrollment":150},{"nctId":"NCT06833112","phase":"PHASE4","title":"Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital Of Guizhou Medical University","startDate":"2025-02","conditions":"Ankylosing Spondylitis","enrollment":10},{"nctId":"NCT01086059","phase":"","title":"OTIS Humira Pregnancy Registry","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2003-11","conditions":"Crohn's Disease, Rheumatoid Arthritis","enrollment":944},{"nctId":"NCT05350644","phase":"","title":"Inflammatory Bowel Disease(IBD), Treatment Response","status":"TERMINATED","sponsor":"University of Southern Denmark","startDate":"2022-02-08","conditions":"Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease","enrollment":2},{"nctId":"NCT03976245","phase":"PHASE4","title":"Advanced Therapeutics in Rheumatoid Arthritis (RA)","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2020-03-01","conditions":"Rheumatoid Arthritis","enrollment":144},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT06642207","phase":"","title":"Effect of IL17 Inhibitor in Comparison With Anti-TNF in Patients With Ankylosing Spondylitis","status":"RECRUITING","sponsor":"Sohag University","startDate":"2024-10-01","conditions":"Ankylosing Spondylitis","enrollment":50},{"nctId":"NCT04347798","phase":"","title":"IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2020-11-01","conditions":"Covid-19 Infection, Rheumatoid Arthritis, Psoriatic Arthritis","enrollment":773},{"nctId":"NCT06601595","phase":"","title":"Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital","status":"NOT_YET_RECRUITING","sponsor":"Mohamed Nasr","startDate":"2024-10","conditions":"Inflammatory Bowel Disease (IBD), Spondylarthropathies, TNF-alpha Inhibitors","enrollment":100},{"nctId":"NCT06563635","phase":"","title":"Frequency of Tuberculosis in Psoriasis Patients","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2023-05-01","conditions":"Psoriasis Vulgaris, Tuberculosis","enrollment":719},{"nctId":"NCT04152980","phase":"PHASE3","title":"Pentoxifylline Dose Optimization in Neonatal Sepsis","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2020-01-12","conditions":"Neonatal Late Onset Sepsis","enrollment":30},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT06507891","phase":"PHASE1, PHASE2","title":"A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-07-06","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT01242488","phase":"PHASE2","title":"Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":221},{"nctId":"NCT02450513","phase":"","title":"Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2012-03","conditions":"Crohn's Disease","enrollment":30},{"nctId":"NCT03652961","phase":"PHASE4","title":"Rheumatoid Arthritis Memory B Cells and Abatacept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-02","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT04731831","phase":"","title":"Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.","status":"RECRUITING","sponsor":"Aalborg University Hospital","startDate":"2020-08-01","conditions":"Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondylitis, Ankylosing","enrollment":120},{"nctId":"NCT06446219","phase":"","title":"Efficacy and Safety Comparison of Upadacitinib and Vedolizumab in Second-line Treatment for Crohn's Disease","status":"COMPLETED","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2020-01-01","conditions":"Crohn Disease","enrollment":172},{"nctId":"NCT06400589","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease","status":"SUSPENDED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2024-05-01","conditions":"Dry Eye","enrollment":750},{"nctId":"NCT06433869","phase":"PHASE2","title":"The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-14","conditions":"Malignant Ascites","enrollment":60},{"nctId":"NCT04721821","phase":"","title":"Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-01-22","conditions":"Arthritis Rheumatoid","enrollment":7807},{"nctId":"NCT06299631","phase":"","title":"Endoscopic Relapse Risks Evaluation After Ileocolic Resection for Crohn's Disease","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2015-01","conditions":"Crohn's Disease","enrollment":133},{"nctId":"NCT03839862","phase":"","title":"Faecal Analyses in Spondyloarthritis Therapy","status":"RECRUITING","sponsor":"Region Skane","startDate":"2019-01-01","conditions":"Spondyloarthropathies, Ankylosing Spondylitis","enrollment":50},{"nctId":"NCT05447182","phase":"","title":"People-Powered Medicine (PPM): Rheumatoid Arthritis Non-responders to Biologic Therapies (RANT)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-06","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15},{"nctId":"NCT05653011","phase":"","title":"Predictors of Prognosis in IBD Patients","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2013-03-11","conditions":"Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease","enrollment":100},{"nctId":"NCT06177405","phase":"","title":"Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors","status":"COMPLETED","sponsor":"Institute of Biomedical Chemistry, Russia","startDate":"2021-01-15","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT05702879","phase":"","title":"Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success","status":"UNKNOWN","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-09-06","conditions":"Ulcerative Colitis","enrollment":240},{"nctId":"NCT00741910","phase":"PHASE2","title":"Extension Study of Semapimod 60 mg IV x 3 Days","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2003-07","conditions":"Crohn's Disease","enrollment":15},{"nctId":"NCT06109961","phase":"PHASE1, PHASE2","title":"Hyperbaric Oxygen Therapy for Perianal Fistulizing Crohn's Disease Not Responsive or Intolerant to Conventional Care: HYPNOTIC Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2024-01","conditions":"Inflammatory Bowel Disease (IBD)","enrollment":40},{"nctId":"NCT00116272","phase":"","title":"Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-04","conditions":"Pregnancy","enrollment":830},{"nctId":"NCT02760433","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2017-01-25","conditions":"Rheumatoid Arthritis","enrollment":368},{"nctId":"NCT03227419","phase":"PHASE4","title":"Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders","status":"UNKNOWN","sponsor":"Lille Catholic University","startDate":"2018-01-22","conditions":"Arthritis, Rheumatoid","enrollment":224},{"nctId":"NCT03293784","phase":"PHASE1","title":"TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2017-10-16","conditions":"Melanoma","enrollment":33},{"nctId":"NCT04255134","phase":"PHASE4","title":"Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2020-09-07","conditions":"Rheumatoid Arthritis","enrollment":18},{"nctId":"NCT02144857","phase":"PHASE4","title":"Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2014-05-30","conditions":"Psoriasis","enrollment":200},{"nctId":"NCT03619876","phase":"PHASE4","title":"Effects of Abatacept on Myocarditis in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Columbia University","startDate":"2019-07-10","conditions":"Rheumatoid Arthritis, Myocardial Inflammation","enrollment":11},{"nctId":"NCT05767814","phase":"","title":"Optimization of Psoriatic and Seronegative Rheumatoid Arthritis Patients Selection and Treatment Outcomes of Biologic Therapies.","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2019-10-03","conditions":"Psoriatic Arthritis, Rheumatoid Arthritis","enrollment":135},{"nctId":"NCT05182203","phase":"","title":"Safety and Retention Rate of the JAK and TNF Inhibitors in Rheumatoid Arthritis: a Real-life Experience","status":"COMPLETED","sponsor":"Tuen Mun Hospital","startDate":"2022-03-01","conditions":"Rheumatoid Arthritis, Drug Use","enrollment":1732},{"nctId":"NCT03941496","phase":"PHASE1, PHASE2","title":"Azacytidine During Anti-tuberculosis Therapy","status":"WITHDRAWN","sponsor":"Andrew Dinardo","startDate":"2022-10","conditions":"Tuberculosis, Pulmonary","enrollment":0},{"nctId":"NCT05651373","phase":"","title":"The Clinical Features and Pregnancy Outcomes of RA Patients","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-07-30","conditions":"Rheumatoid Arthritis, Pregnancy Related","enrollment":100},{"nctId":"NCT00048321","phase":"PHASE2","title":"ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2002-01-01","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT02374021","phase":"PHASE4","title":"Treatments Against RA and Effect on FDG-PET/CT","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-07","conditions":"Arthritis, Rheumatoid","enrollment":159},{"nctId":"NCT03589833","phase":"PHASE4","title":"Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2019-05-14","conditions":"Arthritis, Rheumatoid","enrollment":504},{"nctId":"NCT05567380","phase":"","title":"Comparative Study of Janus Kinase (JAK) Inhibitors Vs Tumor Necrosis Factor (TNF) Inhibitors in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-10","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT03351647","phase":"","title":"Predictive Factors of Clinical Response to Ustekinumab in Active Crohn's Disease","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-02-14","conditions":"Crohn Disease","enrollment":18},{"nctId":"NCT03690544","phase":"PHASE4","title":"Apremilast for RAS","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-10-12","conditions":"Recurrent Aphthous Stomatitis","enrollment":15},{"nctId":"NCT03331393","phase":"","title":"The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-16","conditions":"Rheumatoid Arthritis","enrollment":265},{"nctId":"NCT04798287","phase":"","title":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-10","conditions":"Rheumatoid Arthritis","enrollment":105711},{"nctId":"NCT05424393","phase":"","title":"Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-03-04","conditions":"Rheumatoid Arthritis","enrollment":500},{"nctId":"NCT03033095","phase":"NA","title":"Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2016-07","conditions":"Spondylitis, Ankylosing","enrollment":50}],"_emaApprovals":[{"date":"","name":"TNF Inhibitor","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL3897557","moleculeType":"Unknown","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL3897557"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":1317,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 19","pmid":"41856561","title":"Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial.","journal":"RMD open"},{"date":"2026 Mar","pmid":"41852927","title":"Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial.","journal":"EClinicalMedicine"},{"date":"2026","pmid":"41836530","title":"From Methotrexate Resistance to Biologic and Targeted Pharmacotherapy: A Decade of Phase 4 Clinical Trials Evidence in Rheumatoid Arthritis.","journal":"Drug design, development and therapy"},{"date":"2026 Mar 13","pmid":"41825927","title":"Mortality incidence in spondyloarthritis: real-world evidence using the TriNetX Global Collaborative Network.","journal":"RMD open"},{"date":"2026 Mar 7","pmid":"41795040","title":"Prognostic Factors for Sideroblastic Anemia with B-cell Immunodeficiency, Periodic Fevers, and Developmental Delay Due to TRNT1 Gene Mutations: A Case Report and Systematic Review.","journal":"Journal of clinical immunology"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"17767.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":16,"withResults":5},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:32:32.803662+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}